ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 258 filers reported holding ACCELERON PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $36,000 | +140.0% | 209 | +74.2% | 0.00% | – |
| Q2 2021 | $15,000 | -6.2% | 120 | 0.0% | 0.00% | – |
| Q1 2021 | $16,000 | +14.3% | 120 | +6.2% | 0.00% | – |
| Q4 2020 | $14,000 | -63.2% | 113 | -66.6% | 0.00% | – |
| Q3 2020 | $38,000 | +40.7% | 338 | +12.7% | 0.00% | -100.0% |
| Q2 2020 | $27,000 | 0.0% | 300 | 0.0% | 0.00% | – |
| Q1 2020 | $27,000 | +68.8% | 300 | 0.0% | 0.00% | – |
| Q4 2019 | $16,000 | +23.1% | 300 | -8.8% | 0.00% | – |
| Q3 2019 | $13,000 | -7.1% | 329 | 0.0% | 0.00% | – |
| Q2 2019 | $14,000 | -6.7% | 329 | 0.0% | 0.00% | – |
| Q1 2019 | $15,000 | +36.4% | 329 | +31.6% | 0.00% | – |
| Q4 2018 | $11,000 | -21.4% | 250 | 0.0% | 0.00% | – |
| Q3 2018 | $14,000 | +16.7% | 250 | 0.0% | 0.00% | – |
| Q2 2018 | $12,000 | +20.0% | 250 | 0.0% | 0.00% | – |
| Q1 2018 | $10,000 | – | 250 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |